Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 9, 2013, Pages 5255-5259

  Liu, Zheng Bing ^a   Shu, Jun ^a   Wang, Li Ping ^a   Jin, Cheng ^a   Lou, Zhi Xia ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 2A6 (CYP2A6); Lung cancer; Meta analysis; Polymorphism

Indexed keywords

CYTOCHROME P450 2A6;

ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOCHROME P450 2A6 GENE; ETHNICITY; GENE DELETION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOME DELETION; COMPUTATIONAL BIOLOGY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MODELS, GENETIC; ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 84883303721     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2625-0     Document Type: Article

References (27)

1. Chiu YH, Spiegelman D, Dockery DW et al (2011) Secondhand smoke exposure and inflammatory markers in nonsmokers in the trucking industry. Environ Health Perspect 119(9):1294-1300
2. Wang J, Chen JP, Chen X et al (2011) Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 6(12):e28844
3. Chen Z, Li Z, Niu X et al (2011) The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. Mutagenesis 26(3):437-446
4. Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6(12):947-960
5. Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q et al (2008) Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 83(1):115-121
6. Oscarson M (2001) Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29(2):91-95
7. Wassenaar CA, Dong Q, Wei Q et al (2011) Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 103(17):1342-1346
8. Takeshita H, Hieda Y, Fujihara J et al (2006) CYP2A6 polymorphism reveals differences in Japan and the existence of a specific variant in Ovambo and Turk populations. Hum Biol 78(2):235-242
9. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-102
10. Banerjee I (2010) Relationship between paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis. Eur J Epidemiol 25(7):449-458
11. Thakkinstian A, McElduff P, D'Este C et al (2005) A method for meta-analysis of molecular association studies. Stat Med 24(9):1291-1306
12. Beger C, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 151:419-463
13. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
14. Tamaki Y, Arai T, Sugimura H et al (2011) Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet 26(5):516-522
15. Wang H, Tan W, Hao B et al (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63(22):8057-8061
16. Loriot MA, Rebuissou S, Oscarson M et al (2001) Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11(1):39-44
17. Tan W, Chen GF, Xing DY et al (2001) Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 95(2):96-101
18. Kamataki T, Fujita K et al (2002) Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev 34(3):667-676
19. Gu Y, Zhang S, Lai B et al (2004) Frequency of CYP2A6 gene deletion and in relation to risk of lung cancer. Tuber Thor Tumor 2:111-117
20. Ariyoshi N, Miyamoto M, Umetsu Y et al (2002) Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 11(9):890-894
21. Fujieda M, Yamazaki H, Saito T et al (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25(12):2451-2458
22. DeVore NM, Scott EE (2012) Nicotine and 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. J Biol Chem 287(32):26576-26585
23. Gheona A, Daniel R, Shoshana Z (2011) Relationship between CYP2a6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis. IMAJ 13(2):87-90
24. Nunoya K, Yokoi T, Kimura K et al (1998) A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 8(3):239-249
25. Fernander A, Schumacher M, Wei X et al (2008) Smoking risk and the likelihood of quitting among African-American female light and heavy smokers. J Natl Med Assoc 100(10):1199-1206
26. Nakada T, Kiyotani K, Iwano S et al (2012) Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. J Toxicol Sci 37(3):555-563
27. Derby KS, Cuthrell K, Caberto C et al (2008) Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 17(12):3526-3535